ReviewStem cell reports2021
The Organoid Platform: Promises and Challenges as Tools in the Fight against COVID-19.
Review in Stem cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- When stem cells meet COVID-19: recent advances, challenges and future perspectives.Stem cell research & therapy · 2022Pooled it
- Organoids at the forefront of global health: accelerated research and ethical implications in the cases of Zika and COVID-19.Global public health · 2025Article
- Article
- Review
- Article
- Engineering functional 3-dimensional patient-derived endocrine organoids for broad multiplatform applications.Surgery · 2023Article
- Mechanical stretching boosts expansion and regeneration of intestinal organoids through fueling stem cell self-renewal.Cell regeneration (London, England) · 2022Article
- 100 plus years of stem cell research-20 years of ISSCR.Stem cell reports · 2022Review
- The SARS-CoV-2 receptor ACE2 is expressed in mouse pericytes but not endothelial cells: Implications for COVID-19 vascular research.Stem cell reports · 2022Article
- Article
- Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection.International journal of molecular sciences · 2022Article
- Human Organoids as a Promising Platform for Fighting COVID-19.International journal of biological sciences · 2022Review
- Microfluidic Tools for Enhanced Characterization of Therapeutic Stem Cells and Prediction of Their Potential Antimicrobial Secretome.Antibiotics (Basel, Switzerland) · 2021Article
- Organoids and Colorectal Cancer.Cancers · 2021Review
- Defense of COVID-19 by Human Organoids.Phenomics (Cham, Switzerland) · 2021Review
- Current Trends and Research Topics Regarding Intestinal Organoids: An Overview Based on Bibliometrics.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many pathogenic viruses that affect man display species specificity, limiting the use of animal models. Studying viral biology and identifying potential treatments therefore benefits from the development of in vitro cell systems that closely mimic human physiology. In the current COVID-19 pandemic, rapid scientific insights are of the utmost importance to limit its impact on public health and society. Organoids are emerging as versatile tools to progress the understanding of SARS-CoV-2 biology and to aid in the quest for novel treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.